Analysis of the real clinical treatment effect of Quizartinib

As a selective FLT3-ITD inhibitor, Quizartinib's clinical therapeutic effect has been widely recognized by the international hematology community. FLT3-ITD mutation is one of the most common genetic abnormalities in acute myeloid leukemia (AML). This mutation causes leukemia cells to continue to proliferate and become resistant to traditional chemotherapy. Quizartinib directly inhibits tumor cell proliferation and induces apoptosis by specifically blocking the FLT3 signaling pathway, thereby significantly improving the disease control rate.

Clinical practice shows that quizartinib is particularly effective in patients with relapsed or refractory FLT3 mutant AML. After patients receive quizartinib, hematological remission is usually seen within a few weeks, and some patients can also observe significant improvements in bone marrow morphology. Compared with traditional chemotherapy or first-generation FLT3 inhibitors (such as sorafenib), quizartinib has higher response rates and longer intervals between relapses. In large overseas studies, quizartinib combined with standard induction chemotherapy can prolong median overall survival and significantly reduce the risk of disease progression.

Quizatinib’s clinical advantages are also reflected in its strong targeting and low toxic and side effects. Although some patients may experience mild gastrointestinal discomfort, leukopenia, or QT interval prolongation, most of these side effects are controllable under physician supervision. Its oral administration form also makes treatment more convenient for patients, eliminating the need for long-term hospitalization for chemotherapy, which greatly improves the quality of life.

It is worth noting that quizartinib also shows potential in the maintenance treatment phase. For AML patients who have received hematopoietic stem cell transplantation, quizartinib can delay disease recurrence and improve long-term survival rates. This makes it not only suitable for acute treatment, but also an important candidate for maintenance treatment. Currently, in the United States and Japan, quizartinib has been included in AML treatment guidelines for adult patients with positive FLT3 mutations.

Reference materials:https://go.drugbank.com/drugs/DB12874